<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
RULE 13d-2(a)
(Amendment No. 1 )*
Ilex Oncology, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock
- --------------------------------------------------------------------------------
(Title of Class of Securities)
451923 10 6
- --------------------------------------------------------------------------------
(CUSIP Number)
Phillip H. Watts, Esq., 16825 Northchase Drive, Suite 1300, Houston, TX 77060.
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
March 8, 2000
- --------------------------------------------------------------------------------
(Date of Event which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition that is the subject of this Schedule 13D, and is filing
this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the
following box [ ].
Note: Schedules filed in paper format shall include a signed original
and five copies of the schedule, including all exhibits. See Rule 13d-7(b)
for other parties to whom copies are to be sent.
(Continued on following pages)
(Page 1 of Pages)
- ----------
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE>
SCHEDULE 13D
- ----------------------- ---------------------
CUSIP NO. 451923 10 6 PAGE OF PAGES
- ----------------------- ---------------------
- ------------------------------------------------------------------------------
NAME OF REPORTING PERSON
1 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
US Oncology Research, Inc. (formerly known as PRN Research, Inc.) ("PRNR")
- ------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
2 (a) [_]
(b) [_]
- ------------------------------------------------------------------------------
SEC USE ONLY
3
- ------------------------------------------------------------------------------
SOURCE OF FUNDS*
4
Not Applicable
- ------------------------------------------------------------------------------
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) [_]
5
- ------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
6
PRNR is a Texas corporation
- ------------------------------------------------------------------------------
SOLE VOTING POWER
7
NUMBER OF 0
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 8
0
OWNED BY
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
9
REPORTING 0
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 10
0
- ------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11
0
- ------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
12
[_]
- ------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
13
0%
- ------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
14
CO
- ------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.
<PAGE>
SCHEDULE 13D
- ----------------------- ---------------------
CUSIP NO. 451923 10 6 PAGE OF PAGES
- ----------------------- ---------------------
- ------------------------------------------------------------------------------
NAME OF REPORTING PERSON
1 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
US Oncology, Inc. ("USON")
- ------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
2 (a) [_]
(b) [_]
- ------------------------------------------------------------------------------
SEC USE ONLY
3
- ------------------------------------------------------------------------------
SOURCE OF FUNDS*
4
Not Applicable
- ------------------------------------------------------------------------------
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) [_]
5
- ------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
6
USON is a Delaware corporation.
- ------------------------------------------------------------------------------
SOLE VOTING POWER
7
NUMBER OF 0
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 8
0
OWNED BY
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
9
REPORTING 0
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 10
0
- ------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11
0
- ------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
12
[_]
- ------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
13
0%
- ------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
14
CO HC
- ------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.
<PAGE>
CUSIP No. 451923 10 6 13D Page of Pages
This Amendment No. 1 amends the Schedule 13D filed by the reporting persons
dated August 18, 1999 (the "Schedule"). This Amendment No. 1 is being filed
because the Reporting Persons are no longer subject to the reporting
requirements of Section13(d) of the Securities Exchange Act of 1934 as a result
of the disposition of the 1,255,988 shares of common stock ($.01 par value) of
ILEX Oncology, Inc. previously held by PRNR (the "Shares") pursuant to a sale of
the Shares on March 8, 2000. Other than as set forth below, to the best
knowledge of the Reporting Persons, there has been no material change in the
information set forth in response to Items 1, 3,6 and 7 of the Schedule.
Accordingly, these Items are omitted from this Amendment No. 1.
________________________________________________________________________________
Item 2. Identity and Background.
(a) This Statement is filed by US Oncology, Inc. and US Oncology Research, Inc.
(formerly known as PRN Research, Inc.) (collectively, the "Reporting
Persons").
(b) The principal executive offices of the Reporting Persons are located at
16825 Northchase Drive, Suite 1300, Houston, Texas 77060.
(c) The Reporting Persons provide practice management, administrative and other
services to physician groups specializing in the treatment of cancer. PRNR
is an indirect wholly owned subsidiary of USON focusing on research
activities of managed groups.
Information regarding the foregoing with respect to each of the Officers and
Directors of each of the Reporting Persons is set forth on Schedule A to this
Schedule 13-D.
(d) Neither of the Reporting Persons, nor, to the knowledge of the Reporting
Persons, any of the individuals named on Schedule A hereto, has been
convicted in a criminal proceeding in the past five years (excluding
traffic violations or similar misdemeanors).
(e) During the past five years, neither of the Reporting Persons, nor, to the
knowledge of the Reporting Persons any of the individuals named on Schedule
A hereto, was a party to a civil proceeding of a judicial or administrative
body of competent jurisdiction as a result of which such person was or is
subject to a judgment, decree or final order enjoining future violations
of, or prohibiting or mandating activities subject to, federal or state
securities laws of finding any violation with respect to such laws.
(f) Each of the officers and directors of the Reporting Persons is a United
States citizen.
________________________________________________________________________________
Item 4. Purpose of Transaction.
Not Applicable
________________________________________________________________________________
Item 5. Interest in Securities of the Issuer.
(a) As a result of the disposition of 1,255,988 shares of common stock ($.01
par value) of the Issuer pursuant to the sale of such shares on March 8,
2000, the Reporting Persons do not beneficially own any shares of common
stock ($.01 par value) of the Issuer.
<PAGE>
(b) The Reporting Persons do not have the sole power to vote or to direct the
vote, shared power to vote or to direct the vote, sole power to dispose or
to direct the disposition or shared power to dispose or to direct the
disposition of common stock ($.01 par value) of the Issuer.
(c) Other than the transaction described in this Amendment No. 1, there were no
transactions by any of the Reporting Persons, persons in control of the
Reporting Persons or any of their respective officers and directors in the
common stock ($.01 par value) of the Issuer that were effected during the
past sixty days.
(d) To the best knowledge of the Reporting Persons, no person other than the
Reporting Persons has the right to receive or the power to direct the
receipt of dividends from, or the proceeds from the sale of the common
stock ($.01 par value) of the Issuer that occurred on March 8, 2000.
(e) The Reporting Persons ceased to be the beneficial owner of more than five
percent of the common stock ($.01 par value) of the Issuer on March 8,
2000.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
US Oncology Research, Inc.
/s/ L. FRED POUNDS
- -------------------------------- Dated: March 20, 2000
L. Fred Pounds, Treasurer and ---------------------
Secretary
US Oncology, Inc.
/s/ L. FRED POUNDS
- --------------------------------- Dated: March 20, 2000
L. Fred Pounds, Chief Financial Officer ---------------------
and Vice President of Finance.
Attention. Intentional misstatements or omissions of fact constitute federal
criminal violations (see 18 U.S.C. 1001).
<PAGE>
Schedule A
----------
Officers and Directors of US Oncology Research, Inc.
- ----------------------------------------------------
R. Dale Ross President and Director
Lloyd K. Everson, M.D. Vice President and Director
L. Fred Pounds Treasurer and Secretary and Director
Executive Officers of US Oncology, Inc.
- ---------------------------------------
R. Dale Ross Chairman of the Board and Chief Executive Officer
Lloyd K. Everson, M.D. President
L. Fred Pounds Chief Financial Officer, Vice President of Finance and
Treasurer
Leo E. Sands Chief Compliance Officer
David Chernow President, Physician Services Group and Chief
Development Officer
Joseph S. Bailes, M.D. Executive Vice President
R. Allen Pittman Chief Administrative Officer
Atul M. Dhir, M.D. President, Cancer Information and Research Group
William F. McKeon Senior Vice President for Marketing and eCommerce
Phillip H. Watts General Counsel
Marc I. Kerlin Senior Vice President for Managed Care
Mark E. Ahern Senior Vice President for Development
The present business address of all of the foregoing individuals is 16825
Northchase Drive, Suite 1300, Houston, Texas 77060.
<PAGE>
Directors of US Oncology, Inc.
- ------------------------------
<TABLE>
<CAPTION>
Name Present Business Address Present Principal Occupation
<S> <C> <C>
R. Dale Ross 16825 Northchase Drive, Suite 1300, Chief Executive Officer, US
Houston, Texas 77060 Oncology, Inc.
Nancy Brinker 9410 Alva Court CEO - In Your Corner, Inc., a provider of health
Dallas, Texas 75229 and wellness products and services
Russell L. Carson 320 Park Avenue, Suite 2500 Partner - Welsh, Carson, Anderson & Stowe, an
New York, New York 10022 investment partnership
John T. Casey 16825 Northchase Drive, Suite 1300, Former Chief Executive Officer, Physician Reliance
Houston, Texas 77060 Network, Inc., now a part time employee of
physician Reliance Network, Inc.
J. Taylor Crandall 201 Main Street Vice President and CFO of Keystone, Inc., an
Fort Worth, TX 76102 investment company.
James E. Dalton, Jr. 103 Continental Place President, CEO and Director of Quorum Health
Brentwood, Tennessee 37207 Group, Inc., a health care company
Robert W. Daly 36 Washington Stret, Suite 170 Managing Director, MedEquity Investors, LLC, a
Wellesley Hills, MA 02481 health care venture capital firm.
Stephen E. Jones, M.D. 3535 Worth Street Physician, Texas Oncology, P.A.
Dallas, Texas 75246
Richard B. Mayor 700 Louisiana Ave, Ste. 1900 Of Counsel, Mayor, Day, Caldwell & Keeton, L.L.P.
Houston, Texas 77002
Robert A. Ortenzio 4718 Old Gettysburg Road President and Chief Operating Officer, Select
Mechanicsburg, PA 17055 Medical Corporation
Boone Powell, Jr. 3500 Gaston Avenue President and Chief Executive Officer, Baylor
Dallas, TX 75246 Health Care System and Baylor University Medical
Center
Edward E. Rogoff, M.D. 2625 Craycroft Road, Suite 100 Physician, Southwestern Radiation Oncology, Ltd.
Tucson, AZ 85712
Burton S. Schwartz, M.D. 800 E. 25th Street Physician, Minnesota Oncology Hematology, P.A.
405 Piper Bldg.
Minneapolis, Minnesota 55407
</TABLE>
